Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Grant A. Wintheiser"'
Autor:
Lila J. Finney Rutten, Deirdre R. Pachman, Sandra A. Mitchell, Cindy Tofthagen, Jeph Herrin, Joan M. Griffin, Parvez A. Rahman, Grant A. Wintheiser, Kathryn J. Ruddy, Linda L. Chlan, Aaron L. Leppin, Andrea L. Cheville, Jennifer L. Ridgeway, Minji K. Lee
Publikováno v:
JNCI: Journal of the National Cancer Institute. 114:458-466
Background The symptom burden associated with cancer and its treatment can negatively affect patients’ quality of life and survival. Symptom-focused collaborative care model (CCM) interventions can improve outcomes, but only if patients engage with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b77db484741a170849e3a266df2b0e4
https://doi.org/10.1093/jnci/djab172
https://doi.org/10.1093/jnci/djab172
Autor:
Grant A. Wintheiser, Wil L. Santivasi
Publikováno v:
Mayo Clinic proceedings. 96(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81351c9310ed217ec5428430c040cd5e
https://pubmed.ncbi.nlm.nih.gov/34218865
https://pubmed.ncbi.nlm.nih.gov/34218865
Publikováno v:
Pharmacology & Therapeutics. 224:107823
TAS-102 is an orally administered fixed-dose formulation consisting of trifluorothymidine (TFT), a fluoropyrimidine antimetabolite, and tipiracil (TPI), an inhibitor of thymidine phosphorylase (TP) that prevents rapid degradation of TFT and ensures i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1e4ae8e9a65ff4844ba0a203158ecb7
https://doi.org/10.1016/j.pharmthera.2021.107823
https://doi.org/10.1016/j.pharmthera.2021.107823